LATAM MedTech Insights

This week, we dive into a sudden and pivotal regulatory shift in Brazil. ANVISA has just launched a new fast-track approval pathway for medium-risk medical devices, a move that could dramatically accelerate market entry. But this opportunity comes with a complex new requirement that is already tripping up unprepared manufacturers.

In this episode, we break down exactly what ANVISA's new resolution entails. We explore the case of a German MedTech firm whose attempt to leverage this new fast-track process was immediately halted by a documentation mistake, highlighting a critical new pain point for foreign companies. This is a must-listen for any regulatory professional eyeing the Brazilian market.

Key Questions from This Episode:

- Does your existing FDA or CE clearance automatically qualify you for ANVISA's new fast-track process?

- What is the single most common error companies are making in the new 'Comparative Regulatory Analysis' report?

- How can you leverage your existing technical file to meet the stringent new local requirements in Brazil?

- Why might your standard global registration strategy fail under this new Brazilian rule?

- What specific expertise is now essential for a successful and speedy submission to ANVISA?

- Is it possible to get your device approved in Brazil in under six months, and what's the secret?

Navigating global markets requires more than just a great product; it demands flawless regulatory execution. At Pure Global, we provide end-to-end regulatory consulting, acting as your local representative in over 30 markets, including Brazil. We combine local expertise with advanced AI tools to streamline market access, manage technical dossiers, and ensure your submission is right the first time. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dissect the critical new amendment to Brazil's RDC 657 software regulations, a move by ANVISA that specifically targets AI and machine learning devices. The update introduces complex new requirements for clinical validation, post-market changes, and cybersecurity, significantly raising the bar for market entry.

We explore what these changes mean for MedTech manufacturers, why Brazil is becoming one of the most demanding markets for digital health, and how companies can adapt their strategies to succeed.

**Case Study:**

Imagine your AI-powered diagnostic software, already successful in Europe and the US, is ready for its Brazilian launch. Suddenly, ANVISA's new amendment invalidates your entire clinical data package and demands a brand-new, localized study. How do you manage this unexpected, multi-million dollar roadblock without abandoning Latin America's largest market?

**Key Takeaways:**

- Does my AI software now need a separate validation dossier specifically for the Brazilian population?

- What is a "Pre-approved Change Plan" and how do I submit one to ANVISA for my adaptive algorithm?

- Are my current cybersecurity measures compliant with the newly mandated international standards?

- How can I leverage my existing clinical data to meet the new local requirements without starting from scratch?

- What are the new post-market surveillance duties for AI software that learns continuously?

- Will this amendment affect the registration timeline for my non-AI software products as well?

Navigating complex regulatory shifts like these is what we do best. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise in over 30 markets, including Brazil. We use advanced AI and data tools to streamline your path to market access. Don't let regulatory hurdles block your innovation.

Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dissect breaking news from Brazil. ANVISA, the national health regulatory agency, has just launched a new fast-track pilot program for AI-powered medical software. This move could slash market entry timelines in half, but it comes with a host of new, complex requirements that could trap unprepared companies.

We explore the specific opportunities this creates for MedTech innovators in the diagnostic space and the hidden challenges in clinical data and cybersecurity compliance that lie beneath the surface. This is a must-listen for any company looking to capitalize on Brazil's push to become a digital health powerhouse.

Case Study Spotlight: A Brazilian startup created a revolutionary AI to detect a common cause of blindness. They were facing a two-year regulatory battle, risking their competitive edge. Now, a new door has opened, but it demands a completely different key. How can they pivot their regulatory strategy to meet aggressive new data validation standards without getting lost in the paperwork?

Key Questions Answered:

- What are the exact eligibility criteria for ANVISA's new SaMD fast-track program?

- How does this new pathway impact foreign companies trying to enter the Brazilian market?

- What are the new cybersecurity and data privacy demands hidden within this regulation?

- Is this accelerated process a genuine opportunity or a new regulatory bottleneck?

- How can you leverage existing international approvals, like FDA or CE, for this new process?

- What are the most common mistakes companies make when submitting AI device dossiers in Brazil?

At Pure Global, we specialize in demystifying these complex regulatory shifts. We offer end-to-end solutions, from market strategy and technical dossier preparation using advanced AI tools to serving as your official local representative in Brazil. Ready to accelerate your market access? Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's ANVISA just launched a new fast-track approval process for AI medical software, a huge opportunity for MedTech innovators. However, this golden ticket comes with a major catch: a strict data localization law that could derail market entry plans for unprepared international companies. This episode of LATAM MedTech Insights unpacks the new resolution and explores the critical strategic decisions that foreign device manufacturers now face.

We delve into the dual nature of this regulation. It is both a massive opportunity to accelerate entry into a booming market and a significant operational hurdle that demands a sophisticated, localized strategy.

**Case In Point:** A leading European AI diagnostics firm saw its Brazil market entry timeline cut by 75%, a massive win. The catch? Their entire cloud-based system is suddenly non-compliant under the new data sovereignty rules, forcing a painful and expensive choice: build local infrastructure from scratch or miss the window of opportunity entirely.

**Key Takeaways From This Episode:**

- What are the exact technical requirements of ANVISA's new resolution for AI software?

- How can you leverage the new fast-track approval without falling into the data localization trap?

- Is it more cost-effective to partner locally or build your own data infrastructure in Brazil?

- What are the hidden cybersecurity compliance costs associated with this new rule?

- How does this Brazilian policy signal a larger regulatory trend across Latin America?

- What are the three critical questions your legal and IT teams should be asking right now?

- Can your existing technical dossier be adapted for this new, faster submission process?

- What are the IP protection risks when partnering with local data providers?

At Pure Global, we specialize in turning these regulatory challenges into market opportunities. We provide end-to-end solutions, from developing a compliant regulatory strategy and managing technical submissions with our AI-powered tools, to acting as your official local representative in Brazil. We help you navigate complex requirements like data localization so you can access new markets faster and with confidence. Contact us to learn how we can streamline your global expansion at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the seismic shift in Brazil's regulatory landscape. Last week, ANVISA issued an unexpected technical note on clinical evaluation requirements under RDC 751, fundamentally altering the path to market for many international device manufacturers. We explore the end of the 'easy' equivalence route based on CE or FDA clearance and what this means for your technical dossier, budget, and timeline. This isn't just a minor update; it's a strategic challenge that redefines market entry into Latin America's largest economy. Imagine you're a US-based orthopedic company, weeks away from submitting your dossier to ANVISA, only to find your entire clinical strategy, built on equivalence to your CE-marked device, is now invalid. We discuss the real-world scramble this has caused. In This Episode, We Uncover: 1. What specific clause in the new ANVISA note created this regulatory hurdle? 2. Why is relying on your existing CE mark or FDA 510(k) for equivalence in Brazil now a critical risk? 3. What are the three immediate strategic options for manufacturers affected by this change? 4. How does this shift impact the timeline and cost for new device registrations in Brazil? 5. Is it still possible to use the equivalence pathway, and if so, what is the new gold standard for a predicate device? 6. What does this move signal about ANVISA's long-term regulatory direction? 7. How can you proactively monitor for these kinds of 'surprise' updates from regulatory bodies? Navigating sudden regulatory shifts in LATAM requires more than just knowledge; it requires on-the-ground intelligence and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline global market access. Whether it's developing a new clinical strategy for Brazil or managing submissions across 30+ markets, we are your local representative. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence.

Brazil's ANVISA just opened a fast-track approval process for AI medical devices, creating a huge opportunity for MedTech innovators. But this incredible speed comes with a hidden challenge: a new set of ultra-stringent cybersecurity regulations that are catching many companies off guard and threatening to derail their launch plans.

Imagine a US-based scaleup, CardioVision AI, ready to enter Brazil with their FDA-cleared diagnostic software. They see ANVISA's new fast-track and are excited for a quick launch. But their team suddenly discovers the new rules demand a level of data encryption and mandatory local data hosting they hadn't prepared for. Their entire market entry timeline is now at risk, and the costs are mounting. This is the exact challenge many companies are now facing.

Key Takeaways:

- What are the exact requirements of ANVISA's new fast-track AI approval pathway?

- How do the new Brazilian cybersecurity mandates compare to FDA and EU standards?

- What are the biggest compliance mistakes companies make when entering this new pathway?

- Is local data hosting now a non-negotiable for AI medical devices in Brazil?

- How can you leverage your existing technical dossier for this new, faster submission?

- What specific documentation is ANVISA demanding to prove cybersecurity robustness?

- Are there hidden costs associated with meeting these new stringent requirements?

- How can you prepare your Quality Management System for these specific AI regulations?

Struggling to navigate these complex regulatory changes in Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline your global market access. To learn how we can help you successfully launch in Brazil and beyond, contact us at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the groundbreaking new regulations for AI-powered medical devices just announced by Brazil's ANVISA. This move positions Brazil at the forefront of digital health governance in Latin America, but it also creates a complex new landscape for manufacturers to navigate.

We break down what these changes mean, from updated cybersecurity mandates to new requirements for algorithmic transparency. We also explore the immediate impact on MedTech innovators who are looking to enter the lucrative, yet challenging, Brazilian market.

Imagine your company has a revolutionary AI diagnostic tool and you were on the verge of entering the Brazilian market. Suddenly, you face a completely new set of rules. Your original submission is now obsolete, your timeline is shattered, and you risk losing your first-mover advantage. How do you adapt your strategy without going back to square one?

This week's key takeaways:

- What are the three most critical changes in ANVISA's new SaMD framework?

- How does the new regulation affect different classes of AI-driven medical devices?

- What are the unspoken cybersecurity vulnerabilities that ANVISA is trying to address?

- Is Brazil's new stance a barrier to entry or a gateway for serious MedTech companies?

- How can you leverage your existing technical documentation for the new submission process?

- What are the biggest potential pitfalls in the new clinical data requirements?

- Does this regulatory shift signal a larger trend across other LATAM markets?

Navigating these shifts requires deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local experts with advanced AI tools to streamline market access. Don't let regulatory hurdles slow your growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can help you succeed in Brazil and over 30 other markets worldwide.

In this episode, we dissect the immediate impact of Brazil's new ANVISA resolution, RDC 848/2024. This isn't just another regulatory update; it's a fundamental shift in how Brazil evaluates the safety and performance of medical devices, with a sharp new focus on lifecycle risk management and cybersecurity.

We explore how this change disrupts the conventional market entry strategy for international MedTech companies. A previously straightforward submission process now requires a new level of evidence, particularly for connected devices and Software as a Medical Device (SaMD), creating unforeseen delays and costs for those unprepared.

**Key Questions Answered:**

* Why is Brazil's RDC 848/2024 more than just a standard update?

* What are the new, unwritten cybersecurity requirements ANVISA now expects for SaMD?

* How does this resolution impact your existing FDA or CE-marked technical files?

* Is your current risk management plan now obsolete for the Brazilian market?

* What specific threat modeling is now necessary for connected devices?

* How can you prevent a six-month delay on your product launch in Brazil?

* What are the hidden compliance costs associated with this new regulation?

Navigating these complex changes requires deep local expertise and a proactive strategy. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Let us help you turn regulatory hurdles into market opportunities. Contact us at [email protected] or visit https://pureglobal.com/.

This week, we dive into a game-changing regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just launched a new "reliance pathway," promising to dramatically accelerate market access for high-risk medical devices that have already been approved by authorities like the US FDA. This could slash years off of registration timelines.

In this episode, we unpack the reality behind the hype. We explore the massive opportunities this creates for international manufacturers and the critical details that could make or break a successful submission. Learn what "essentially identical" really means for your product and why local compliance is more important than ever, even with this new shortcut.

**What You'll Learn:**

1. What is ANVISA's new reliance pathway and which foreign approvals are accepted?

2. How much faster can your Class III or IV device get to market under this new rule?

3. What are the most common "hidden hurdles" that could disqualify you from the optimized review?

4. Does your product's indication for use perfectly match your foreign approval?

5. Why is a local Brazil Registration Holder (BRH) still absolutely essential for success?

6. How does this change the strategic importance of Brazil in your global expansion plans?

7. What are the key differences between the reliance dossier and a standard submission?

Navigating regulatory shifts like Brazil's new reliance pathway is critical for market success. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI to streamline market access across more than 30 countries. Let us be your local representative in Brazil and ensure your submission is optimized for the fastest possible approval. Contact us at [email protected] or visit https://pureglobal.com/ to secure and accelerate your market presence.

Brazil just rewrote the rules for digital health. Last week, ANVISA published its new regulatory framework for Software as a Medical Device (SaMD), creating an urgent new landscape for MedTech companies. This update introduces a new risk classification system, expedited pathways for some devices, and significant new hurdles for high-risk AI and machine learning technologies.

This episode of LATAM MedTech Insights unpacks the critical details of this regulatory shift. We explore the specific requirements that international companies must meet, including the complex pre-approval process for algorithm changes and the stringent new data privacy rules tied to Brazil's LGPD. For companies in the digital health space, understanding these changes is not just important, it's essential for survival and success in Latin America's largest market.

**Key Takeaways From This Episode:**

* How does Brazil's new four-tier risk classification for SaMD differ from the FDA and MDR frameworks?

* What is an 'Algorithm Change Protocol' and why is it now a mandatory submission for AI-driven devices?

* Are there new data localization requirements under the updated cybersecurity rules?

* Which types of SaMD can now benefit from an expedited registration pathway?

* How will ANVISA's new rules impact the use of foreign clinical data in submissions?

* What are the immediate compliance risks for devices already on the Brazilian market?

* Why is a local representative more critical than ever under this new framework?

**Unlock Global Markets with Pure Global**

Navigating complex regulatory shifts like Brazil's new SaMD framework is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline global market access. From initial strategy and technical dossier submission to post-market surveillance and local representation, we are your partner in over 30 markets worldwide. Don't let regulatory hurdles slow your growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure your entry into the LATAM market and beyond.